In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.
2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
A large proportion of patients with systemic lupus erythematosus (SLE) have been inappropriately prescribed opioids, researchers reported recently in the Morbidity and Mortality Weekly Report.
ACR Annual Meeting: In patients with moderate to severe systemic lupus erythematosus, anifrolumab (AstraZeneca) was superior to placebo for overall disease activity, skin disease and oral corticosteroid tapering, among other efficacy endpoints, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: At the American College of Rheumatology annual meeting in Atlanta today, Dr. Konstantinos Tselios of the University of Toronto addresses the challenges associated with developing new treatments for systemic lupus.
Availability of new dosages for hydroxychloroquine—a first-line therapy for systemic lupus—may be best for patients, shows a survey conducted by the Lupus Foundation of America.
While significant advances have been made in the treatment of systemic lupus erythematosus (SLE), the highly variable manifestations of the disease make treatment difficult.
Low-dose IL-2 might be effective and tolerated in the treatment of systemic lupus erythematosus (SLE), say researchers writing in Annals of the Rheumatic Disease this month.
Hydroxychloroquine retinopathy is more common than previously thought, shows a study published in Arthritis and Rheumatology. Higher dosages and long duration of use is associated with a higher risk of vision loss.